期刊
PROGRESS IN NEUROBIOLOGY
卷 95, 期 4, 页码 670-685出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pneurobio.2011.04.007
关键词
Multiple sclerosis; Biomarkers; Neurodegeneration
资金
- LOEWE Neuronal Coordination Research Focus Frankfurt (NeFF)
- Merck Inc., USA
- Biogen Idec
- TEVA
- Merck Serono
- Deutsche Forschungsgemeinschaft
- Bayer Schering
- Genzyme-Virotec
- Merck-Serono
- Novartis
- Roche
- TEVA Pharma
- Gemeinnutzige Hertie-Stiftung
- GBS-Polyradiculitis-Stiftung
- University of Ulm
- Landesstiftung BW
Multiple sclerosis (MS) is the most common neurological disorder leading to permanent disability in young adults in the developed world. While traditionally conceived as an autoimmune inflammatory disease it is becoming increasingly evident that axonal and neuronal degeneration occur, at least partly independent of inflammation, and already at the earliest stages of the disease. In addition, it is the progressive neurodegeneration which determines the amount of accumulating clinical disability. Therefore, MS should be considered as a neurodegenerative disorder. Development of disease-modifying drugs to treat MS is currently highly dynamic. Already, several drugs have shown short-term efficacy to delay progression of clinical disability, but the ultimate aim is to halt disease progression. In this context, the development of sensitive, reliable and valid biomarkers to measure neurodegeneration is an indispensible need to facilitate successful informative clinical trials. While no such biomarker is currently fully established, several promising candidate biomarkers obtained with multimodal techniques, including cerebrospinal fluid and serum analysis, neuroimaging and neurophysiology, are presently developed and evaluated. This paper compiles an up-to-date critical review of the available knowledge of candidate biomarkers of neurodegenerative processes in MS. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据